Symptoms of indwelling ureteral stent. Infection and inflammatory reaction due to prosthetic device, implant and graft in urinary system - Unspecified complication of genitourinary prosthetic device, implant and graft
Conditions
Interventions
Intervention 1: Tamsulosin 0.4mg capsule at bedtime for 4 weeks. Intervention 2: Tolterodine 2mg tablet two times a day (morning , evening) for 4 weeks. Intervention 3: A capsule of Starch daily for 4
Treatment - Drugs
Placebo
Tamsulosin 0.4mg capsule at bedtime for 4 weeks
Tolterodine 2mg tablet two times a day (morning , evening) for 4 weeks
A capsule of Starch daily for 4 weeks
Sponsors
Vice-chancellor for research, Kermanshah University of Medical Sciences and Health Services
Eligibility
Sex/Gender
All
Age
16 Years to 100 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Ureteral stenting for treatment of ureteral obstruction due to upper tract urinary stone (kidney or ureter) Exclusion criteria: history of urinary system surgery, BPH (IPSS>7), long standing lower urinary tract symptoms, Indwelling ureteral stent at presentation, treatment with NSAIDs or Alpha-blockers, advanced cardiac or hepatic disease, Pregnancy
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Relieving of indwelling ureteral stent symptoms. Timepoint: 1 week and 4 weeks after insertion, 1 week after removal. Method of measurement: Ureteral stent symptom score questionnaire (USSQ). | — |
Secondary
| Measure | Time frame |
|---|---|
| Presence of indwelling ureteral stent symptoms in spite of medication. Timepoint: 1 week and 4 weeks after insertion, 1 week after removal. Method of measurement: Ureteral stent symptom score questionnaire (USSQ). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Mahmoudreza Moradi
Kermanshah University of Medical Sciences and Health Services
Outcome results
None listed